Request for a sample: https://www.psmarketresearch.com/market-analysis/3d-bioprinting-market/report-sample
The 3D bioprinting market size is projected to reach $792.5 million by 2022, growing at a CAGR of 35.9% between 2016-2022. The market is driven by factors, such as technological advancements and innovations, increasing compliance for drug discovery processes, and high demand for organ and tissue transplantation.
The 3D bioprinting finds application in government tissue & organ regeneration, 3D cell culture, pharmaceutical, and others. The tissue and organ regeneration segment accounted for the major share in the 3D bioprinting market in 2015; whereas, 3D cell culture witnessed the fastest growth.
3D bioprinting has opened up new platforms in the drug discovery and development process. Many drugs are withdrawn or not approved by regulatory authority due to their toxicity to certain organ such as liver, which could not be predicted during the pre-clinical trial process. Tissues developed through 3D bioprinting such as liver tissue help to predict drug toxicity and improve drug efficacy.
Some of the major players operating in the 3D bioprinting market include Organovo Holdings, Inc., CELLINK, EnvisionTEC, BioBots, Cyfuse Biomedical K.K., Aspect Biosystems Ltd., 3D Bioprinting Solutions, Ourobotics, Advanced Solutions, Inc., GeSiM, Bio3D Technologies, 3Dynamic Systems Ltd., Nano3D Biosciences, Inc., Poietis, regenHU Ltd., and Aerotech Inc.